134 related articles for article (PubMed ID: 30871861)
41. Hippocampal orexin receptors inactivation reduces PTZ induced seizures of male rats.
Goudarzi E; Elahdadi Salmani M; Lashkarbolouki T; Goudarzi I
Pharmacol Biochem Behav; 2015 Mar; 130():77-83. PubMed ID: 25600753
[TBL] [Abstract][Full Text] [Related]
42. In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist.
Beuckmann CT; Suzuki M; Ueno T; Nagaoka K; Arai T; Higashiyama H
J Pharmacol Exp Ther; 2017 Aug; 362(2):287-295. PubMed ID: 28559480
[TBL] [Abstract][Full Text] [Related]
43. Orexin/Hypocretin-1 Receptor Antagonism Selectively Reduces Cue-Induced Feeding in Sated Rats and Recruits Medial Prefrontal Cortex and Thalamus.
Cole S; Mayer HS; Petrovich GD
Sci Rep; 2015 Nov; 5():16143. PubMed ID: 26536818
[TBL] [Abstract][Full Text] [Related]
44. A selective orexin-1 receptor antagonist attenuates stress-induced hyperarousal without hypnotic effects.
Bonaventure P; Yun S; Johnson PL; Shekhar A; Fitz SD; Shireman BT; Lebold TP; Nepomuceno D; Lord B; Wennerholm M; Shelton J; Carruthers N; Lovenberg T; Dugovic C
J Pharmacol Exp Ther; 2015 Mar; 352(3):590-601. PubMed ID: 25583879
[TBL] [Abstract][Full Text] [Related]
45. Role of orexin-2 and CB1 receptors within the periaqueductal gray matter in lateral hypothalamic-induced antinociception in rats.
Esmaeili MH; Reisi Z; Ezzatpanah S; Haghparast A
Behav Pharmacol; 2017 Feb; 28(1):83-89. PubMed ID: 27906750
[TBL] [Abstract][Full Text] [Related]
46. Orexin 2 receptor regulation of the hypothalamic-pituitary-adrenal (HPA) response to acute and repeated stress.
Grafe LA; Eacret D; Luz S; Gotter AL; Renger JJ; Winrow CJ; Bhatnagar S
Neuroscience; 2017 Apr; 348():313-323. PubMed ID: 28257896
[TBL] [Abstract][Full Text] [Related]
47. Identification of highly selective and potent orexin receptor 1 antagonists derived from a dual orexin receptor 1/2 antagonist based on the structural framework of pyrazoylethylbenzamide.
Futamura A; Nozawa D; Araki Y; Tamura Y; Tokura S; Kawamoto H; Tokumaru Y; Kakihara S; Aoki T; Ohtake N
Bioorg Med Chem; 2017 Oct; 25(20):5203-5215. PubMed ID: 28807572
[TBL] [Abstract][Full Text] [Related]
48. Discovery of orexin 2 receptor selective and dual orexin receptor agonists based on the tetralin structure: Switching of receptor selectivity by chirality on the tetralin ring.
Iio K; Saitoh T; Ohshita R; Hino T; Amezawa M; Takayama Y; Nagumo Y; Yamamoto N; Kutsumura N; Irukayama-Tomobe Y; Ishikawa Y; Tanimura R; Yanagisawa M; Nagase H
Bioorg Med Chem Lett; 2022 Mar; 60():128555. PubMed ID: 35051577
[TBL] [Abstract][Full Text] [Related]
49. Orexin Plays a Role in Growth Impediment Induced by Obstructive Sleep Breathing in Rats.
Tarasiuk A; Levi A; Assadi MH; Troib A; Segev Y
Sleep; 2016 Apr; 39(4):887-97. PubMed ID: 26943473
[TBL] [Abstract][Full Text] [Related]
50. Nonpeptide Orexin-2 Receptor Agonist Attenuates Morphine-induced Sedative Effects in Rats.
Toyama S; Shimoyama N; Tagaito Y; Nagase H; Saitoh T; Yanagisawa M; Shimoyama M
Anesthesiology; 2018 May; 128(5):992-1003. PubMed ID: 29521652
[TBL] [Abstract][Full Text] [Related]
51. Evidence for orexinergic mechanisms in migraine.
Hoffmann J; Supronsinchai W; Akerman S; Andreou AP; Winrow CJ; Renger J; Hargreaves R; Goadsby PJ
Neurobiol Dis; 2015 Feb; 74():137-43. PubMed ID: 25447225
[TBL] [Abstract][Full Text] [Related]
52. Orexin Receptor Antagonists: Historical Perspectives and Future Opportunities.
Andrews SP; Aves SJ; Christopher JA; Nonoo R
Curr Top Med Chem; 2016; 16(29):3438-3469. PubMed ID: 26416477
[TBL] [Abstract][Full Text] [Related]
53. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
Hoyer D; Jacobson LH
Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
[TBL] [Abstract][Full Text] [Related]
54. Binge-like consumption of ethanol and other salient reinforcers is blocked by orexin-1 receptor inhibition and leads to a reduction of hypothalamic orexin immunoreactivity.
Olney JJ; Navarro M; Thiele TE
Alcohol Clin Exp Res; 2015 Jan; 39(1):21-9. PubMed ID: 25623402
[TBL] [Abstract][Full Text] [Related]
55. Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist.
Glen A; Bürli RW; Livermore D; Buffham W; Merison S; Rowland AE; Newman R; Fieldhouse C; Miller DJ; Dawson LA; Matthews K; Carlton MB; Brice NL
Bioorg Med Chem Lett; 2024 Mar; 100():129629. PubMed ID: 38295907
[TBL] [Abstract][Full Text] [Related]
56. [Effect of orexin-A and orexin-1 receptor antagonist injected into the fourth ventricle of rats on food-intake and spontaneous physical activity].
Peng XY; Guo FF; Sun XR; Gong YL; Xu L
Sheng Li Xue Bao; 2015 Aug; 67(4):379-85. PubMed ID: 26300249
[TBL] [Abstract][Full Text] [Related]
57. Discovery of novel orexin receptor antagonists using a 1,3,5-trioxazatriquinane bearing multiple effective residues (TriMER) library.
Saitoh T; Amezawa M; Horiuchi J; Nagumo Y; Yamamoto N; Kutsumura N; Ohshita R; Tokuda A; Irukayama-Tomobe Y; Ogawa Y; Ishikawa Y; Hasegawa E; Sakurai T; Uchida Y; Sato T; Gouda H; Tanimura R; Yanagisawa M; Nagase H
Eur J Med Chem; 2022 Oct; 240():114505. PubMed ID: 35839689
[TBL] [Abstract][Full Text] [Related]
58. Mechanistic insights into mode of action of a potent natural antagonist of orexin receptor-1 by means of high throughput screening and molecular dynamics simulations.
Dhanjal JK; Grover S; Paruthi P; Sharma S; Grover A
Comb Chem High Throughput Screen; 2014 Feb; 17(2):124-31. PubMed ID: 24090103
[TBL] [Abstract][Full Text] [Related]
59. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
[TBL] [Abstract][Full Text] [Related]
60. Design and synthesis of novel orexin 2 receptor agonists with a 1,3,5‑trioxazatriquinane skeleton.
Amezawa M; Yamamoto N; Nagumo Y; Kutsumura N; Ishikawa Y; Yanagisawa M; Nagase H; Saitoh T
Bioorg Med Chem Lett; 2023 Feb; 82():129151. PubMed ID: 36690040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
